Not available
Quote | Amarin Corporation plc (NASDAQ:AMRN)
Last: | $0.7963 |
---|---|
Change Percent: | 1.42% |
Open: | $0.78 |
Close: | $0.7963 |
High: | $0.8183 |
Low: | $0.7725 |
Volume: | 699,144 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | Amarin Corporation plc (NASDAQ:AMRN)
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
Message Board Posts | Amarin Corporation plc (NASDAQ:AMRN)
Subject | By | Source | When |
---|---|---|---|
"Stay with the program"? What's that supposed | FlyFishingStocks | investorshub | 07/26/2024 9:57:01 PM |
le pain et le loueil d'olive is optional | Gusman | investorshub | 07/26/2024 9:50:29 PM |
Wow thats as close to Spain as you | rosemountbomber | investorshub | 07/26/2024 9:05:40 PM |
Can only hope they nail this guy and | ramfan60 | investorshub | 07/26/2024 8:52:17 PM |
Come on France! Pull your Head Out! | CaptBeer | investorshub | 07/26/2024 8:25:58 PM |
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...